The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Should imporvement in rheumatoid arthritis clinical trials be defined as fifty percent or seventy percent improvement in core set measures, rather than twenty percent?
Abstract
OBJECTIVE: To determine whether the initiation of corticosteroids or other types of therapy affects the development of scleroderma renal crisis (SRC). METHODS: Using a case-control study, 110 patients with systemic sclerosis who developed SRC between 1981 and 1993 were closely matched with controls on sex, race, age, disease duration, skin score, levels of creatine phosphokinase, and presence of tendon friction rubs. Corticosteroid use was determined prior to the onset of SRC in cases or prior to the first visit in controls. Cases were compared with matched controls using McNemar's matched-pair analysis and conditional logistic regression analysis. The effects of other drugs, including D-penicillamine, nonsteroidal antiinflammatory drugs (NSAIDs), calcium channel blockers, and angiotensin-converting enzyme (ACE) inhibitors, were also evaluated. RESULTS: In the 6 months prior to SRC onset or to the first visit, high-dose corticosteroids (> or =15 mg/day prednisone or equivalent) were administered significantly more frequently in SRC patients (36%) than in the controls (12%) (McNemar's odds ratio 4.37, 95% confidence interval 2.03-9.43, P < 0.0001). New use of low-dose steroids, continuous use of any steroid dose, NSAIDs, calcium channel blockers, and ACE inhibitors were not associated with an increased risk of SRC. Antecedent D-penicillamine therapy may have been protective against the development of SRC in controls. CONCLUSION: This retrospective case-control study has shown a significant association between antecedent high-dose corticosteroid therapy and the development of SRC. These results should discourage the use of high-dose corticosteroids in patients with early diffuse scleroderma who are at increased risk of developing SRC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inhibition of Prostaglandin Synthesis as a Mechanism of Action for Aspirin-like Drugs
VANE, J. R. (1971) · Nature New Biology · doi:10.1038/newbio231232a0 · Cited by 8,605
de Waal Malefyt, R., Abrams, J., Bennett, B., Figdor, C. G., & de Vries, J. E. (1991) · The Journal of experimental medicine · doi:10.1084/jem.174.5.1209 · Cited by 3,762
Elliott, M. J., Maini, R. N., Feldmann, M., Kalden, J. R., Antoni, C., Smolen, J. S., Leeb, B., Breedveld, F. C., Macfarlane, J. D., Bijl, J. A., et al. (1994) · The Lancet · doi:10.1016/s0140-6736(94)90628-9 · Cited by 1,682
Self-citationMitchell, J. A., Akarasereenont, P., Thiemermann, C., Flower, R. J., & Vane, J. R. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.24.11693 · Cited by 1,659
Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and nonulcerogenic.
Masferrer, J. L., Zweifel, B. S., Manning, P. T., Hauser, S. D., Leahy, K. M., Smith, W. G., Isakson, P. C., & Seibert, K. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.8.3228 · Cited by 1,310
Self-citationRisk of Alzheimer's disease and duration of NSAID use
Stewart, W. F., Kawas, C., Corrada, M., & Metter, E. J. (1997) · Neurology · doi:10.1212/wnl.48.3.626 · Cited by 1,132
Elevated cerebrospinal fluid levels of substance p in patients with the fibromyalgia syndrome
Russell, I. J., Orr, M. D., Littman, B., Vipraio, G. A., Alboukrek, D., Michalek, J. E., Lopez, Y., & Mackillip, F. (1994) · Arthritis & Rheumatism · doi:10.1002/art.1780371106 · Cited by 679
Steen, V. D., Costantino, J. P., Shapiro, A. P., & Medsger, T. A. (1990) · Annals of Internal Medicine · doi:10.7326/0003-4819-113-5-352 · Cited by 441
Spertini, O., Luscinskas, F. W., Kansas, G. S., Munro, J. M., Griffin, J. D., Gimbrone, M. A., & Tedder, T. F. (1991) · The Journal of Immunology · doi:10.4049/jimmunol.147.8.2565 · Cited by 394
CANNON, P. J., HASSAR, M., CASE, D. B., CASARELLA, W. J., SOMMERS, S. C., & LeROY, E. C. (1974) · Medicine · doi:10.1097/00005792-197401000-00001 · Cited by 343
D-Penicillamine Therapy in Progressive Systemic Sclerosis (Scleroderma): A Retrospective Analysis
STEEN, V. D., MEDSGER, T. A., & RODNAN, G. P. (1982) · Annals of Internal Medicine · doi:10.7326/0003-4819-97-5-652 · Cited by 322
Normotensive renal failure in systemic sclerosis
Helfrich, D. J., Banner, B., Steen, V. D., & Medsger, T. A. (1989) · Arthritis & Rheumatism · doi:10.1002/anr.1780320911 · Cited by 217
Autoantibody Reactive with RNA Polymerase III in Systemic Sclerosis
Okano, Y., Steen, V. D., & Medsger, T. A. (1993) · Annals of Internal Medicine · doi:10.7326/0003-4819-119-10-199311150-00007 · Cited by 207
Cognitive‐behavioral approaches to pain management in rheumatoid arthritis
Parker, J. C., Iverson, G. L., Smarr, K. L., & Stucky‐ropp, R. C. (1993) · Arthritis & Rheumatism · doi:10.1002/art.1790060407 · Cited by 25
Research works printed but not linked: 18
- Felson, 1995, Arthritis Rheum, 38, 727, 10.1002/art.1780380602 · DOI · Paper page
- Felson, 1993, Arthritis Rheum, 36, 729, 10.1002/art.1780360601 · DOI · Paper page
- Pillemer, 1993, Arthritis Rheum, 40, 419, 10.1002/art.1780400305 · doi:10.1002/art.1780400305
- Moreland, 1997, N Engl J Med, 337, 141, 10.1056/NEJM199707173370301 · DOI · Paper page
- Van den Borne, 1996, Scand J Rheumatol, 25, 307, 10.3109/03009749609104063 · DOI
- Paulus, 1990, Arthritis Rheum, 33, 477, 10.1002/art.1780330403 · DOI · Paper page
- O'Dell, 1997, Arthritis Rheum, 40, 842, 10.1002/art.1780400510 · DOI · Paper page
- Ferracciolo, 1997, Arthritis Rheum, 40, s219
- Bombardier, 1982, J Rheumatol, 9, 753
- Arnett, 1988, Arthritis Rheum, 31, 315, 10.1002/art.1780310302 · DOI · Paper page
- Williams, 1985, Arthritis Rheum, 28, 721, 10.1002/art.1780280702 · DOI · Paper page
- Williams, 1983, Arthritis Rheum, 26, 581, 10.1002/art.1780260502 · DOI
- Ward, 1983, Arthritis Rheum, 26, 1303, 10.1002/art.1780261102 · DOI · Paper page
- Weinblatt, 1990, Arthritis Rheum, 33, 330, 10.1002/art.1780330305 · doi:10.1002/art.1780330305
- Tugwell, 1995, N Engl J Med, 333, 137, 10.1056/NEJM199507203330301 · DOI · Paper page
- Felson, 1990, Arthritis Rheum, 33, 1449, 10.1002/art.1780331001 · DOI · Paper page
- Felson, 1992, Arthritis Rheum, 35, 1117, 10.1002/art.1780351003 · DOI · Paper page
- The arcsine transformation and the effect size index. In: Statistical power analysis for the behavioral science. 2nd ed. Hillsdale (NJ): Lawrence Erlbaum Associates; 1988. p. 180-5.
Cited by
Aletaha, D., Neogi, T., Silman, A. J., Funovits, J., Felson, D. T., Bingham, C. O., Birnbaum, N. S., Burmester, G. R., Bykerk, V. P., Cohen, M. D., et al. (2010) · Arthritis & Rheumatism · doi:10.1002/art.27584 · Cited by 9,619
Self-citationAletaha, D., Neogi, T., Silman, A. J., Funovits, J., Felson, D. T., Bingham, C. O., Birnbaum, N. S., Burmester, G. R., Bykerk, V. P., Cohen, M. D., et al. (2010) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.138461 · Cited by 4,941
Self-citationInfliximab and Methotrexate in the Treatment of Rheumatoid Arthritis
Lipsky, P. E., van der Heijde, D. M. F. M., St. Clair, E. W., Furst, D. E., Breedveld, F. C., Kalden, J. R., Smolen, J. S., Weisman, M., Emery, P., Feldmann, M., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011303432202 · Cited by 2,996
The Effect of Celecoxib, a Cyclooxygenase-2 Inhibitor, in Familial Adenomatous Polyposis
Steinbach, G., Lynch, P. M., Phillips, R. K. S., Wallace, M. H., Hawk, E., Gordon, G. B., Wakabayashi, N., Saunders, B., Shen, Y., Fujimura, T., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200006293422603 · Cited by 2,526
TNF-mediated inflammatory disease
Bradley, Jr. (2008) · The Journal of Pathology · doi:10.1002/path.2287 · Cited by 2,094
Metadata
- Authors
- Felson, D. T., Anderson, J. J., Lange, M. L. M., Wells, G., & LaValley, M. P.
- Venue
- Arthritis & Rheumatism
- Publisher
- Wiley
- Published
- 1998-09
- Volume
- 41
- Issue
- 9
- Pages
- 1564-1570
- ISSN
- 0004-3591 (ISSN-L)
- 1529-0131
- DOI
- 10.1002/1529-0131(199809)41:9
- OpenAlex
- W2159860060
- Cited by
- 474
- References
- 14
- FWCI
- 5.87
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- doi.wiley.com/10.1002/tdm_license_1.1 (tdm, 6209 d)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.